|
|
|
| ERBB3 expression in thyroid cancer and its significance |
| WANG Yan* YANG Longyan* SUN Rongxin ZHANG Yuanyuan FU Ying ZHAO Dong▲ |
| Endocrine Metabolism and Immunization Center, Luhe Hospital, Capital Medical University, Beijing 101149, China |
|
|
|
Abstract To investigate the effect and function of ERBB3 in the occurrence and development of thyroid cancer at clinical level. Methods The fine needle puncture tissues of 4 patients with thyroid cancer and 6 patients with thyroid nodule in Department of Endocrinology, Beijing Luhe Hospital from December 2017 to December 2018 were collected, RNA-seq was detected and ERBB3 levels were analyzed. The thyroid cancer database of TCGA and the thyroid cancer database of GEO were used to analyze and compare the levels of ERBB3 in patients with recurrent and paracancer, T and N stages. Gene enrichment analysis was used to analyze the relationship between ERBB3 level and EGFR, PI3K and ERK1/2 signaling pathways, as well as the relationship between tumor proliferation and metastasis. Results ERBB3 mRNA was increased in thyroid cancer compared with benign thyroid nodules (P ＜ 0.001). Compared with paracancer, ERBB3 mRNA was elevated in thyroid cancer tissues (TCGA source, P ＜ 0.0001; GEO source, P ＜ 0.0001). In thyroid cancer patients, EGFR, PI3K and ERK1/2 gene sets were significantly enriched in patients with high ERBB3 expression. ERBB3 levels increased with the increase of T staging (P ＜ 0.0001), and the gene sets associated with proliferation were significantly enriched in patients with high ERBB3 expression. Compared with the N0 group, the level of ERBB3 in patients with stage N1 was significantly increased (P ＜ 0.0001). The gene sets associated with metastasis were significantly enriched in patients with high ERBB3 expression. ERBB3 levels were elevated in patients with recurrent thyroid cancer (P = 0.0124). Conclusion ERBB3 may be involved in the proliferation, metastasis and recurrence of thyroid cancer and is expected to be a new target for the treatment of thyroid cancer.
|
|
|
|
|
|
[1] 王宇.甲状腺癌发病率为何越来越高[N].家庭医生报，2019.
[2] Hynes，NE，MacDonald G. ErbB receptors and signaling pathways in cancer [J]. Curr Opin Cell Biol，2009，21（2）：177-184.
[3] Wang Z. ErbB Receptors and Cancer [J]. Methods Mol Biol，2017，1652：3-35.
[4] Ahmed A. Prevalence of Her3 in gastric cancer and its association with molecular prognostic markers：a Saudi cohort based study [J]. Libyan J Med，2019，14（1）：1574532.
[5] Wu X，Chen Y，Li G，et al. Her3 is associated with poor survival of gastric adenocarcinoma：Her3 promotes proliferation，survival and migration of human gastric cancer mediated by PI3K/AKT signaling pathway [J]. Med Oncol，2014，31（4）：903.
[6] Bourillon L，Bourgier C，Gaborit N，et al. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer [J]. Int J Cancer，2019， 145（7）：1838-1851.
[7] Camblin AJ，Pace EA，Adams S，et al. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer [J]. Clin Cancer Res，2018，24（12）：2873-2885.
[8] Ji，ZC，Han SH，Xing YF. Overexpression of miR-3196 suppresses cell proliferation and induces cell apoptosis through targeting ERBB3 in breast cancer [J]. Eur Rev Med Pharmacol Sci，2018，22（23）：8383-8390.
[9] He G，Di X，Yan J，et al. Silencing human epidermal growth factor receptor-3 radiosensitizes human luminal A breast cancer cells [J]. Cancer Sci，2018，109（12）：3774-3782.
[10] Kang YY，Liu Y，Wang ML，et al. Construction and analyses of the microRNA-target gene differential regulatory network in thyroid carcinoma [J]. PLoS One，2017，12（6）：e0178331.
[11] Tao T，Yang X，Zheng J，et al. PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation [J]. Oncogene，2017， 36（44）：6119-6131.
[12] Jian H，Han Y，Yu Y，et al. Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations：afatinib in ERBB+ lung squamous cell carcinoma [J]. Anticancer Drugs，2019，30（8）：873-878.
[13] Soosanabadi M，Mirfakhraie R，Atanesyan L，et al. Application of Multiplex Ligation-Dependent Probe Amplification in Determining the Copy Number Alterations of HER Gene Family Members in Invasive Ductal Breast Carcinoma [J]. Rep Biochem Mol Biol，2019，8（1）：91-101.
[14] Plowman GD，Whitney GS，Neubauer MG，et al. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene [J]. Proc Natl Acad Sci U S A，1990，87（13）：4905-4909.
[15] Mishra R，Patel H，Alanazi S，et al. HER3 signaling and targeted therapy in cancer[J]. Oncol Rev，2018，12（1）：355.
[16] Amin DN，Campbell MR，Moasser MM. The role of HER3，the unpretentious member of the HER family，in cancer biology and cancer therapeutics [J]. Semin Cell Dev Biol，2010，21（9）：944-950.
[17] Kennedy SP，Han JZR，Portman N，et al. Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer [J]. Breast Cancer Res，2019，21（1）：43.
[18] Brizzolara A，Benelli R，Venè R，et al. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer [J]. Cancer Lett，2017，400：9-17.
[19] Phill AG，Findlay MP，Burge ME，et al. Phase Ⅱ Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab （ME-HD7945A） versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer [J]. Clin Cancer Res，2018，24（10）：2276-2284.
[20] Prigent SA，Lemoine NR，Hughes CM，et al. Expression of the c-erbB-3 protein in normal human adult and fetal tissues [J]. Oncogene，1992，7（7）：1273-1278.
[21] Song J，Chai YJ，Masuoka H，et al. Ultrasound image analysis using deep learning algorithm for the diagnosis of thyroid nodules [J]. Medicine （Baltimore），2019，98（15）：e15133.
[22] Luo J，Zhang C，Huang F，et al. Risk of malignancy in thyroid nodules：predictive value of puncture feeling of grittiness in the process of fine-needle aspiration [J]. Sci Rep，2017，7（1）：13109. |
|
|
|
